Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB

Wednesday, March 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study on ALG-000184 (300 mg) ± Entecavir shows significant declines in HBV antigens in untreated HBeAg-positive subjects with chronic hepatitis B (CHB). This indicates a promising potential for the treatment of chronic HBV infection. The results may enhance management strategies for patients with this condition.
Price reaction · baseline $24.5275 (2024-03-27T17:41:00.000Z) · hit during market hours · 2 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Substantial declines in HBV antigens observed.
  • Study focuses on untreated HBeAg-positive subjects.
  • Potential for improved chronic HBV management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a treatment being studied for its effects on HBV antigens.

Who were the subjects in the study?

The study focused on untreated HBeAg-positive subjects with chronic HBV.

What were the results of the study?

The study showed substantial declines in HBV antigens.

What is the significance of these results?

These results indicate potential advancements in chronic HBV management.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 Entecavir HBV chronic hepatitis B HBeAg-positive
Last updated: Mar 27, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →